Sarepta at new high on eteplirsen, Prosensa's drisapersen data
This article was originally published in Scrip
Exactly one year after Sarepta Therapeutics saw its value triple based on 48-week, Phase II clinical trial data for its Duchenne muscular dystrophy (DMD) drug, the company's stock price reached a new high on 3 October based on the latest six-minute walk test (6MWT) and dystrophin results for eteplirsen and the competing DMD therapy drisapersen.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.